non-valvular atrial fibrillation
Conditions
Interventions
A:rivaroxaban 15mg
B:rivaroxaban 15mg
Sponsors
Zhejiang Hospital
Eligibility
Sex/Gender
All
Age
65 Years to 90 Years
Inclusion criteria
Inclusion criteria: age older than 65; BMI 18-24kg/m2; non-valvular atrial fibrillation.
Exclusion criteria
Exclusion criteria: Patients would be ineligible if they had received a therapeutic dose of low-molecular-weight heparin,or unfractionated heparin for more than 48 hours; or if they had any contrainidcation listed in the local labeling of enoxaparin, warfarin, or acenocoumarol. Other criteria for ineligiblity were another indication for vitamin K antagonist; a creatinine clearance below 30ml per minute; clinically significant liver disease or an alanine aminotransferase level that was more than three times the upper limit of the normal range; acitve bleeding or a high risk of bleeding contraindicating anticoagulant treatment; concomitant use of a strong inhibitor of cytochrome P-450 3A4 or a CYP3A4 inducer; participation in another experimental pharmacotherapeutic program within 30 days; or a life expectancy of less than 3 months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| plasma concentration of drug; | — |
Countries
China
Contacts
Public ContactJing Yan
Outcome results
None listed